Periocular injection a feasible route for CNV treatment

The size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid but not into the retina.

The size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid but not into the retina, according to a report published in the February issue of the Journal of Ocular Pharmacology and Therapeutics.

Anna Demetriades and colleagues from the John Hopkins University, School of Medicine, Baltimore, US conducted a study to investigate the penetration of various proteins into a mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein.

Following a periocular injection of AdsFlt-1.10, AdTGF ß.10 or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor- ß (TGF- ß) were not significantly different from scleral levels, and choroidal levels of sFlt-1 were only moderately reduced from scleral levels. However, retinal levels of each of these proteins were low compared with choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked two hours after injection and returned to baseline between six and 24 hours. Peak levels in the retina were 8.6% of peak choroidal levels.

This study suggests that periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but further investigations are required before they could be considered for the treatment of retinal disease.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Noninfectious uveitis, uveitic macular oedema: A synopsis of frontline therapies
Archway: Phase 3 end-of-trial results show Port Delivery System is noninferior to monthly ranibizumab
Clinical trial offers insight into development of KSI-301
© 2023 MJH Life Sciences

All rights reserved.